1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GH’s Phase IIb Data Show Potential Differentiation In Depression

 
• By Joseph Haas

Seeking to bring its psychedelic candidate to market in treatment-resistant depression, Ireland’s GH sees its drug-device inhalation combo product as offering strong differentiation versus Spravato.

GH Research hopes to soon start Phase III in treatment-resistant depression

GH Research PLC reported positive Phase IIb data on 3 February for GH-001 (mebufotenin), an inhalation formulation of the psychedelic compound synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in treatment-resistant depression (TRD), a readout that one analyst said “reinforces GH-001’s blockbuster potential.”

Key Takeaways
  • GH reports Phase IIb data showing that its inhalable psychedelic drug can offer quick and durable benefit in treatment-resistant depression.

During a same-day investor call, GH CEO Velichka Valcheva talked up the drug-device candidate’s prospects for taking on Johnson &...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

More from Therapy Areas

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.